Year: 2019

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – October 31, 2019

Written by Customer Service on December 30, 2019. Posted in Earnings Releases And Operating Results.

EVENTS IN SECOND QUARTEROasmia ADSs were delisted from NASDAQ in the US to reduce complexity and costs.Oasmia recruited two General Managers to its management team.Oasmia published its annual report for 2018/2019 and adjusted accounts due to write-downs. The company’s auditors did not recommend former Board to be granted discharge from liability.The special examiner appointed by Oasmia’s Board, Svante Forsberg (Deloitte), submitted his report on investigation of liability issues ahead of the upcoming Annual General Meeting.Oasmia’s Annual General Meeting resolved to grant the present Board members, elected at the EGM on March 19, 2019, and the former CEO discharge from liability towards the company for the management for the period covered by the Annual Report. The AGM resolved to not grant discharge from liability for...

Oasmia Pharmaceutical AB (publ) Delårsrapport för perioden 1 maj – 31 oktober 2019

Written by Customer Service on December 30, 2019. Posted in Earnings Releases And Operating Results.

HÄNDELSER UNDER ANDRA KVARTALETOasmias depåbevis avnoterades från NASDAQ i USA för att minska komplexitet och kostnader.Oasmia rekryterade två General Managers till bolagets ledningsgrupp. Oasmia publicerade sin årsredovisning för 2018/2019 och reviderade räkenskaper efter nedskrivningar. Bolagets revisor avstyrkte beviljande av ansvarsfrihet för tidigare styrelse.Den av Oasmias styrelse anlitade särskilde granskaren, Svante Forsberg (Deloitte), lämnade sin rapport kring utredning av ansvarsfrågor inför kommande årsstämma.Årsstämman i Oasmia beslutade att bevilja de nuvarande styrelseledamöterna, valda vid den extra bolagsstämman den 19 mars 2019, och den tidigare verkställande direktören ansvarsfrihet gentemot bolaget...

Bone Therapeutics SA: Information on the total number of voting rights and shares

Written by Customer Service on December 30, 2019. Posted in Public Companies.

Regulated informationGosselies, Belgium, 30 December 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares on 18 December 2019 following the conversion of convertible bonds issued on the private placement on 7 March 2018. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.(1) On 12 December 2019, the Extraordinary General Shareholders Meeting approved...

Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions

Written by Customer Service on December 30, 2019. Posted in Public Companies.

Information réglementéeGosselies, Belgique, le 30 décembre 2019, 07h00 CET – BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de thérapies cellulaires et biologiques innovantes répondant à d’importants besoins médicaux non satisfaits dans les domaines de l’orthopédie et des maladies osseuses, annonce aujourd’hui une augmentation du nombre total de droits de vote et d’actions suite à l’émission de nouvelles actions le 18 décembre 2019. L’émission des nouvelles actions est le résultat de la conversion des obligations convertibles émises dans le cadre d’un placement privé...

Isracann Provides Year End Review

Written by Customer Service on December 30, 2019. Posted in Public Companies.

VANCOUVER, British Columbia, Dec. 30, 2019 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales is pleased to extend, on behalf of its executive leadership team, seasons greetings and a review of the Company’s 2019 activities and outlook for the New Year.Mr. Darryl Jones, Isracann’s CEO comments, “It is with great pleasure that we present this review today. Our collective vision, planning and actions to-date have kept us extremely busy in the execution of our strategic plan, which is evident by the many milestones we have achieved in just one fiscal quarter since our public listing. In large part, this review...

Vodafone partners with Nokia to deliver 5G

Written by Customer Service on December 30, 2019. Posted in Public Companies.

Press Release

Norsk Hydro: Production resumed at Paragominas and Alunorte

Written by Customer Service on December 28, 2019. Posted in Public Companies.

The power supply to Hydro’s Paragominas bauxite mine has been resumed, allowing production to restart. Production is consequently being ramped up at Hydro’s Alunorte alumina refinery.On December 18, a transmission tower overturned, ceasing power supply to Paragominas, temporarily halting the production at the mine. The transmission tower has been repaired, and the power connection resumed.There were no personnel injuries, damages to other production assets or impact on the nearby environment related to the power outage.Financial and operational impact has been limited, and no negative customer impact is expected. Investor contactContact Stian HasleCellular +47 97736022E-mail Stian.Hasle@hydro.comPress contactContact Halvor MollandCellular +47 92979797E-mail Halvor.Molland@hydro.com

Norsk Hydro: Produksjonen gjenopptatt ved Paragominas og Alunorte

Written by Customer Service on December 28, 2019. Posted in Public Companies.

Strømtilførselen til Hydros bauksittgruve Paragominas i Brasil har blitt gjenopptatt og produksjonen har startet opp. Produksjonen ved Hydros aluminaraffineri Alunorte vil som en konsekvens også bli normalisert. En høyspentmast som veltet 18. desember førte til strømbrudd for Paragominas og stanset midlertidig produksjonen ved gruven. Høyspentmasten har nå blitt reparert og strømtilførselen er gjenopprettet. Det var ingen personskader, skader på produksjonsutstyr eller innvirkning på nærmiljøet relatert til strømbruddet.Den finansielle og operasjonelle effekten fra strømstansen har vært begrenset og Hydro venter ikke at kunder blir negativt påvirket av strømstansen.InvestorkontaktStian Hasle+47 97736022Stian.Hasle@hydro.comPressekontaktHalvor...

China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies

Written by Customer Service on December 28, 2019. Posted in Public Companies.

Second BeiGene-discovered drug to receive regulatory approval, first in ChinaTislelizumab is an anti–PD-1 antibody specifically designed to minimize binding to FcγR on macrophagesBEIJING, China and CAMBRIDGE, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) as a treatment for patients with classical Hodgkin’s lymphoma (cHL) who have received at least two prior therapies. The new drug application (NDA) was previously granted priority review by the NMPA. Following the recent...

Isabelle Marcoux, Chair of the Board of TC Transcontinental, appointed Member of the Order of Canada

Written by Customer Service on December 28, 2019. Posted in Public Companies.

MONTREAL, Dec. 27, 2019 (GLOBE NEWSWIRE) — TC Transcontinental (TSX: TCL.A TCL.B) is proud to announce that Isabelle Marcoux, Chair of its Board of Directors, has been appointed Member of the Order of Canada. This is the second generation of this family of entrepreneurs to be granted this prestigious Canadian honour. Her father, Rémi Marcoux, founder of TC Transcontinental and a Director on its board, was invested into the Order of Canada himself in 2007. Like her father who founded the company, Ms. Marcoux is in turn deeply committed today to the sustained development of TC Transcontinental, a Québec Inc. corporation based in Montréal with a presence throughout North America, as well as within her community. Isabelle Marcoux’s career has been marked by many professional and philanthropic...

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Year: 2019

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals